Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL

X
Trial Profile

VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Colecalciferol (Primary) ; Omega-3-acid ethyl esters (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms VITAL-DEP
  • Most Recent Events

    • 27 Aug 2024 Planned End Date changed from 1 Feb 2025 to 1 Apr 2025.
    • 12 Dec 2021 Primary endpoint has not been met (Mood scores) as per results published in the JAMA: the Journal of the American Medical Association
    • 12 Dec 2021 Primary endpoint has not been met (Depression) as per results published in the JAMA: the Journal of the American Medical Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top